Skip to main content
Have a personal or library account? Click to login
Latin-American Registry of Cardiovascular Disease and COVID-19: Final Results Cover

Latin-American Registry of Cardiovascular Disease and COVID-19: Final Results

Global Heart
Volume 18 (2023): Issue 1
By: Juan Esteban Gomez-Mesa,  Stephania Galindo,  Manuela Escalante-Forero,  Yorlany Rodas,  Andrea Valencia,  Eduardo Perna,  Alexander Romero,  Iván Mendoza,  Fernando Wyss,  José Luis Barisani,  Mario Speranza,  Walter Alarco and  Noel Alberto Flórez  
Open Access
|Nov 2023
Figures & tables

Figures & Tables

Figure 1

Number of patients by participant countries.

Table 1

Demographic and clinical characteristics at admission of the patients included in this cohort.

VARIABLESN = 3260 n (%)
Age, years (median [IQR])61.0 [48.0, 71.0]
Sex
      Male2059 (63.2)
      Female1201 (36.8)
Weight, kg (median [IQR])75.0 [67.0, 86.0]
Sistolic blood pressure, mmHg (median [IQR])125.0 [112.0, 140.0]
Diastolic blood pressure, mmHg (median [IQR])75.0 [67.0, 83.0]
Heart rate, beats/min (median [IQR])93.0 [80.0, 106.0]
Oxygen saturation, % (median [IQR])91.0 [86.0, 95.0]
Respiratory rate, breaths/min (median [IQR])22.0 [19.0, 28.0]
Fraction of inspired oxygen, % (median [IQR])32.0 [21.0, 85.0]
Overweight/obesity1621 (49.7)
Arterial hypertension1596 (49.0)
Diabetes mellitus869 (26.7)
Dyslipidemia451 (13.8)
Smoking (previous/actual)438 (13.4)
Organ transplant
      Heart9 (0.3)
      Kidney42 (1.3)
      Liver5 (0.2)
      Other4 (0.1)
Asthma/COPD (with/without oxygen)287 (8.8%)
Chronic kidney disease (with/without dialysis)270 (8.3)
Coronary heart disease244 (7.5)
Heart failure182 (5.6)
      LVEF <40%72 (48.0)
      LVEF 40%–50%36 (24.0)
      LVEF >50%42 (28.0)
      Unknown32
Current pregnancy51 (1.6)
Cancer139 (4.3)
Autoimmune disease/immunosuppressant use127 (3.9)
Atrial fibrillation (valvular/non valvular)115 (3.5)
Stroke102 (3.1)
Heart device54 (1.8)
      Implantable cardiodefibrillator (ICD)11 (0.3)
      Cardiac resynchronization Therapy (CRT)1 (0.0)
      Pacemaker39 (1.2)
      ICD/CRT4 (0.1)
HIV infection24 (0.7)
COVID-19 exposure type
      Imported54 (1.9)
      Contact1126 (39.3)
      Circulation1686 (58.8)
      Unknown394
Health care worker
      Yes120 (3.8)
      No3052 (96.2)
      Unknown88
COVID-19 signs and symptoms at admission
      Fever2099 (64.4)
      Cough2235 (68.6)
      Fatigue1625 (49.8)
      Anorexia634 (19.4)
      Myalgias1101 (33.8)
      Diarrhea456 (14.0)
      Chest pain446 (13.7)
      Palpitations151 (4.6)
      Dyspnea2365 (72.5)
      Loss of taste213 (6.5)
      Loss of smell223 (6.8)
      Other1132 (34.7)
Table 2

Diagnostic tests.

VARIABLESn (%)
ECG performed1626 (49.9)
Rhythm, n = 1556
      Sinus rhythm1377 (88.5)
      Ventricular extrasystole27 (1.7)
      Supraventricular extrasystole9 (0.6)
      Atrial fibrillation84 (5.4)
      Atrial flutter7 (0.4)
      Other52 (3.3)
QRS complex (median [IQR]), n = 139390.00 [80.0, 102.0]
Bundle Branch Block, n = 1515
      Right98 (6.5)
      Left47 (3.1)
Corrected QTc interval (median [IQR]), n = 1386419.0 [395.0, 443.0]
Echocardiogram performed634 (19.4)
Systolic function, n = 611
      Focally decreased51 (8.3)
      Globally decreased96 (15.7)
      Normal444 (72.7)
Right ventricular dysfunction, n = 58996 (16.3)
Pericardial effusion, n = 625
      Mild57 (9.1)
      Moderate9 (1.4)
      Severe2 (0.3)
Cardiac tamponade, n = 6182 (0.3)
Severe valvular insufficiency, n = 609
      Mitral11 (1.8)
      Aortic3 (0.5)
      Both2 (0.3)
Severe valvular stenosis, n = 610
      Mitral5 (0.8)
      Aortic12 (2.0)
      Both0 (0.0)
Inferior vena cava dilatation, n = 57690 (15.6)
LVEF (median [IQR]), n = 62160.0 [50.0, 65.0]
TAPSE, mm (mediate [IQR]), n = 36520.0 [17.0, 23.0]
PSAP, mm (median [IQR]), n = 35735.0 [28.0, 45.0]
Strain longitudinal (median [IQR]), n = 3318.0 [16.0, 21.0]
Diameter diastolic vent left, mm (median [IQR]), n = 35046.0 [42.0, 52.0]
Systolic diameter vent left, mm (median [IQR]), n = 32230.0 [27.0, 37.0]
Chest X-ray performed3019 (92.6)
Pulmonary infiltrates
      Unilateral239 (7.3)
      Bilateral2366 (72.6)
Cardiomegaly549 (16.8)
Pulmonary congestion
      Unilateral75 (2.3)
      Bilateral533 (16.3)
Pleural effusion
      Unilateral170 (5.2)
      Bilateral190 (5.8)
Table 3

In-hospital interventions.

VARIABLEN = 3260 n (%)
Invasive Mechanical Ventilation (IMV)1115 (34.2)
IMV days (median [IQR])11.0 [6.0, 19.0]
Vasopressor use900 (27.6)
Vasopressor use days (median [IQR])7.0 [3.0, 12.8]
Inotropic use336 (10.3)
Inotropic use days (median [IQR])5.0 [3.0, 10.0]
Vasodilator use119 (3.7)
Vasodilator use days (median [IQR])3.0 [2.0, 6.0]
Central venous catheter651 (20.0)
Central venous catheter days (median [IQR])12.0 [6.0, 20.0]
Cardioversion/defibrillation106 (3.3)
Coronary arteriography52 (1.6)
Coronary fibrinolysis/thrombolysis31 (1.0)
Coronary angioplasty31 (1.0)
Extracorporeal Oxygenation Membrane (ECMO)29 (0.9)
ECMO days (median [IQR])17.0 [8.0, 28.0]
Intraaortic balloon pump (IABP)2 (0.1)
IABP days (median [IQR])5.0 [4.5, 5.5]
Intensive Care Unit (ICU)1745 (53.5)
ICU days (median [IQR])10.0 [5.0, 18.0]
Table 4

Pharmacological treatment for COVID-19 during hospitalization.

MEDICAMENTS*N = 3260 n (%)
Corticosteroids
      Oral154 (4.7)
      Parenteral2043 (62.7)
Thromboprophylaxis2021 (62.0)
Anticoagulation1257 (38.6)
Azithromycin1096 (33.6)
Hydroxychloroquine690 (21.2)
Lopinovir234 (7.2)
Ritonavir229 (7.0)
Chloroquine90 (2.8)
Plasmapheresis31 (1.0)
Immunoglobulin23 (0.7)
Interferon9 (0.3)
Other1189 (36.5)

[i] *More than one medicament can be administered to patients.

Table 5

Outcomes during hospitalization and 30-day follow up.

VARIABLEN = 3260 n (%)
Condition at discharge
      Alive2304 (70.7)
      Dead831 (25.5)
      Referred123 (3.8)
      Unknown2
Type of death
      Cardiovascular172 (20.7)
      Not cardiovascular659 (79.3)
30 DAYS FOLLOW-UP N = 2427
Condition
      Alive1993 (97.4)
      Dead53 (2.6)
      Unknown381
Type of death
      Cardiovascular11 (20.8)
      Non-cardiovascular42 (79.2)
Rehospitalization 30 days in post-discharge
      Yes144 (7.3)
      No1831 (92.7)
      Unknown452
DOI: https://doi.org/10.5334/gh.1272 | Journal eISSN: 2211-8179
Journal RSS Feed
Language: English
Submitted on: Mar 29, 2023
Accepted on: Sep 25, 2023
Published on: Nov 1, 2023
Published by: Ubiquity Press
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year
Keywords:
Coronavirus,
COVID-19,
Latin America,
Caribbean,
SARS-CoV-2,
Heart Failure

© 2023 Juan Esteban Gomez-Mesa, Stephania Galindo, Manuela Escalante-Forero, Yorlany Rodas, Andrea Valencia, Eduardo Perna, Alexander Romero, Iván Mendoza, Fernando Wyss, José Luis Barisani, Mario Speranza, Walter Alarco, Noel Alberto Flórez, published by Ubiquity Press
This work is licensed under the Creative Commons Attribution 4.0 License.

Volume 18 (2023): Issue 1
Previous article
Next article